This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1989:301:85-96.

Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease

H Sinzinger¹, I Virgolini, J O'Grady

Affiliations

PMID: 2477859

Review

Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease

H Sinzinger et al. Prog Clin Biol Res. 1989.

. 1989:301:85-96.

Authors

H Sinzinger¹, I Virgolini, J O'Grady

Affiliation

¹ Atherosclerosis Research Group, University of Vienna, Austria.

PMID: 2477859

No abstract available

PubMed Disclaimer

Similar articles

Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue.
Kaliman J, Fitscha P, Barth H, Sinzinger H. Kaliman J, et al. Prog Clin Biol Res. 1987;242:469-77. Prog Clin Biol Res. 1987. PMID: 3313421 Clinical Trial. No abstract available.
[Treatment of the peripheral vascular diseases with prostaglandin].
Miyauchi Y. Miyauchi Y. Nihon Rinsho. 1994 Aug;52(8):2182-6. Nihon Rinsho. 1994. PMID: 7933609 Review. Japanese.
Therapeutic effectiveness of prostaglandins (PGs) in peripheral vascular disease (PVD).
Linet OI, Mohberg NR. Linet OI, et al. Adv Prostaglandin Thromboxane Leukot Res. 1989;19:307-10. Adv Prostaglandin Thromboxane Leukot Res. 1989. PMID: 2473609 Clinical Trial. No abstract available.
Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
Müller B, Krais T, Stürzebecher S, Witt W, Schillinger E, Baldus B. Müller B, et al. Biomed Biochim Acta. 1988;47(10-11):S40-4. Biomed Biochim Acta. 1988. PMID: 2470358 Clinical Trial.
[Significance of prostaglandins in arterial occlusive diseases].
Diehm C. Diehm C. Internist (Berl). 1994 Aug;35(8):764-70; discussion 771-2. Internist (Berl). 1994. PMID: 7960555 Review. German. No abstract available.

See all similar articles

Cited by

Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.
Cawello W, Schweer H, Müller R, Bonn R, Seyberth HW. Cawello W, et al. Eur J Clin Pharmacol. 1994;46(3):275-7. doi: 10.1007/BF00192562. Eur J Clin Pharmacol. 1994. PMID: 8070511 Clinical Trial.
Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation.
Cheng Y, Liu M, Hu H, Liu D, Zhou S. Cheng Y, et al. AAPS PharmSciTech. 2016 Apr;17(2):409-17. doi: 10.1208/s12249-015-0366-1. Epub 2015 Jul 21. AAPS PharmSciTech. 2016. PMID: 26195071 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information